{
  "image_filename": "table_p5_det_4_014.png",
  "image_path": "Treanor_et_al.__2011_/extracted/figures/table_p5_det_4_014.png",
  "image_type": "Table",
  "page_number": 5,
  "block_id": "det_4_014",
  "claim_id": "claim_002",
  "claim": "Cell- and egg-based flu vaccines have the potential to develop mutations during production, which may reduce their effectiveness.",
  "supports_claim": false,
  "explanation": "Table presenting the number and percentage of laboratory-confirmed influenza cases (CDC-ILI and illness endpoints) among participants receiving FluBlok (N=2344) versus placebo (N=2304), with calculated vaccine efficacies and 95% confidence intervals for any influenza, influenza A, and influenza B. The table provides clinical efficacy results for an insect cell\u2013derived recombinant influenza vaccine compared to placebo but contains no data or discussion on mutations arising during egg- or cell-based production. It does not support the claim. Note: Image is clear; however, content is limited to efficacy outcomes without addressing production methods or mutation potential.",
  "model_used": "o4-mini",
  "detailed_analysis": {
    "supports_claim": false,
    "image_description": "Table presenting the number and percentage of laboratory-confirmed influenza cases (CDC-ILI and illness endpoints) among participants receiving FluBlok (N=2344) versus placebo (N=2304), with calculated vaccine efficacies and 95% confidence intervals for any influenza, influenza A, and influenza B.",
    "evidence_found": null,
    "reasoning": "The table provides clinical efficacy results for an insect cell\u2013derived recombinant influenza vaccine compared to placebo but contains no data or discussion on mutations arising during egg- or cell-based production. It does not support the claim.",
    "confidence_notes": "Image is clear; however, content is limited to efficacy outcomes without addressing production methods or mutation potential."
  }
}